Echolight, an Italian-based developer of ultrasound-based bone health solutions, has entered into a multiyear agreement to distribute its bone densitometers as part of the Siemens Healthineers women's health portfolio.

The deal enables Siemens Healthineers to resell Echolight’s bone densitometry devices, including the Echos Plus, Echostation, and Echohybrid Plus models. Echolight’s technology, known as Radiofrequency Echographic Multi Spectrometry (REMS), offers a radiation-free alternative to traditional X-ray-based bone density measurements. Instead, the system uses ultrasound to evaluate bone density and microarchitecture at key sites like the spine and femur.

The portable devices simultaneously measure bone mineral density and quality, offering diagnostic metrics like T-scores and Z-scores, as well as a fragility score, which predicts a five-year fracture risk. The ability to bypass common imaging artifacts further enhances diagnostic reliability.
"Bone health is a serious problem here in the U.S.," said Thomas J. McLaughlin, executive commercial director, Echolight USA. "This agreement provides expanded provider and patient access to REMS technology in the U.S. through ultrasound-based bone density scanning as another option in the effort to diagnose and monitor bone health. Echolight is pleased to support Siemens Healthineers in their focus on women's health and bone disease."

Echolight’s U.S. operations, established in 2020, complement its Italian headquarters in Lecce. Its REMS technology has achieved certifications including FDA clearance, CE marking, and ISO 13485:2016.

Ultrasound Homepage